Boston, MA – April 23, 2013 –WorldCare Clinical, LLC (WCC), a leading imaging CRO focused on maximizing the precision and accuracy of independent assessments in clinical trials, today announced it is exhibiting at this week’s 22nd annual Partnerships in Clinical Trials conference at Booth #921. Partnerships is an active community of more than 13,000 members with a worldwide focus on delivering higher quality standards in clinical research and development.
Additionally, WCC joins MGH and Harvard Medical School at the upcoming “Imaging Biomarkers in Clinical Trials – Focus on Oncology,” to be held in the O’Keefe Auditorium at MGH in Boston. The educational format of the conference will give attendees an opportunity to review the current practice of imaging biomarkers in clinical trials in oncology with radiology experts from MGH, as well as discuss advanced imaging techniques that have potential as surrogate biomarkers. Case studies of previous clinical trials and their successes and failures will also be referenced. “Imaging Biomarkers in Clinical Trials” will take place April 26-27, 2013. For more information or to register or to register, visit http://cme.med.harvard.edu/index.asp?SECTION=CLASSES&ID=03324490
About WorldCare Clinical
WorldCare Clinical (WCC) is a leading imaging CRO that employs imaging expertise, innovative technology and operational excellence to maximize the precision and accuracy of a blinded independent central review of clinical trial data. Originally founded in 1992 by the Massachusetts General Hospital (MGH) Department of Radiology, WCC has evolved as an independent company while maintaining a strategic relationship with MGH. With a 20-year focus on imaging trials and their specific requirements, WCC provides sponsors with extensive medical, operational, and image management expertise in support of even the most complex study designs. For more information, visit worldcareclinical.com.
For more information, contact:
SVM Public Relations